BR112018008014A2 - método de identificação de indivíduos portadores de carcinoma e uso de cyfra 21-1 e cea - Google Patents

método de identificação de indivíduos portadores de carcinoma e uso de cyfra 21-1 e cea

Info

Publication number
BR112018008014A2
BR112018008014A2 BR112018008014A BR112018008014A BR112018008014A2 BR 112018008014 A2 BR112018008014 A2 BR 112018008014A2 BR 112018008014 A BR112018008014 A BR 112018008014A BR 112018008014 A BR112018008014 A BR 112018008014A BR 112018008014 A2 BR112018008014 A2 BR 112018008014A2
Authority
BR
Brazil
Prior art keywords
cyfra
cea
carcinoma
identifying individuals
treated
Prior art date
Application number
BR112018008014A
Other languages
English (en)
Inventor
Escherich Achim
Wehnl Birgit
Dayyani Farshid
Herth Felix
Krause Friedemann
Riedlinger Julia
Muley Thomas
ROLNY Vinzent
He Ying
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112018008014A2 publication Critical patent/BR112018008014A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4742—Keratin; Cytokeratin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

a presente invenção refere-se a um método de identificação de indivíduos portadores de carcinoma do pulmão não de células pequenas a serem tratados por meio de quimioterapia com base nas moléculas marcadoras fragmentos de citoqueratina 19 (cyfra 21-1) e antígeno carcinoembriônico (cea), bem como o uso das moléculas marcadoras para identificação de indivíduos a serem tratados por meio de quimioterapia.
BR112018008014A 2015-10-23 2016-10-21 método de identificação de indivíduos portadores de carcinoma e uso de cyfra 21-1 e cea BR112018008014A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15003039 2015-10-23
PCT/EP2016/075313 WO2017068097A1 (en) 2015-10-23 2016-10-21 Methods of identifying an individual as to be treated by chemotherapy based on marker molecules and related uses

Publications (1)

Publication Number Publication Date
BR112018008014A2 true BR112018008014A2 (pt) 2018-10-30

Family

ID=54396694

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018008014A BR112018008014A2 (pt) 2015-10-23 2016-10-21 método de identificação de indivíduos portadores de carcinoma e uso de cyfra 21-1 e cea

Country Status (8)

Country Link
US (1) US11402381B2 (pt)
EP (1) EP3365679B8 (pt)
JP (1) JP7023841B2 (pt)
KR (1) KR102561377B1 (pt)
CN (1) CN108369234B (pt)
BR (1) BR112018008014A2 (pt)
ES (1) ES2856979T3 (pt)
WO (1) WO2017068097A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10390364B2 (en) * 2017-04-18 2019-08-20 Government Of The United States Of America, As Represented By The Secretary Of Commerce Apparatus and method for dynamically controlling spectrum access
US11596694B2 (en) * 2017-09-20 2023-03-07 Mersana Therapeutics, Inc. Compositions and methods for predicting response to NaPi2b-targeted therapy
AU2019320818A1 (en) 2018-08-17 2021-03-11 Mersana Therapeutics, Inc. NaPi2b-targeted polymer antibody-drug conjugates and methods of use thereof
CN110991945B (zh) * 2018-09-30 2023-04-18 北京国双科技有限公司 设备备件的信息处理方法及装置、存储介质和处理器
TWI768713B (zh) * 2021-02-17 2022-06-21 長庚大學 癌症狀態預測方法
CN114113608A (zh) * 2021-11-25 2022-03-01 中国药科大学 一种快速检测肺癌肿瘤标志物的免疫层析试纸条及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5221825B2 (pt) 1973-10-22 1977-06-13
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
GB0224425D0 (en) * 2002-10-21 2002-11-27 Univ Leicester Method for prediction of cardiac disease
US20050244973A1 (en) * 2004-04-29 2005-11-03 Predicant Biosciences, Inc. Biological patterns for diagnosis and treatment of cancer
JP5256284B2 (ja) * 2007-05-18 2013-08-07 デューク ユニバーシティ 肺癌早期発見のための血清バイオマーカー
JP5580205B2 (ja) * 2007-11-19 2014-08-27 セレラ コーポレーション 肺癌マーカーとその使用
EP2071337A1 (en) * 2007-12-10 2009-06-17 F.Hoffmann-La Roche Ag Seprase as a marker for cancer
WO2011140234A1 (en) 2010-05-07 2011-11-10 Abbott Laboratories Methods for predicting sensitivity to treatment with a targeted tyrosine kinase inhibitor
BR112013029787A2 (pt) 2011-05-25 2017-01-17 Novartis Ag biomarcadores para câncer de pulmão
JP5221825B1 (ja) * 2012-10-09 2013-06-26 コニカミノルタホールディングス株式会社 肺扁平上皮癌の検出方法
US20150038365A1 (en) * 2013-08-01 2015-02-05 Meso Scale Technologies, Llc Lung cancer biomarkers

Also Published As

Publication number Publication date
CN108369234A (zh) 2018-08-03
US20180231557A1 (en) 2018-08-16
JP7023841B2 (ja) 2022-02-22
US11402381B2 (en) 2022-08-02
ES2856979T3 (es) 2021-09-28
EP3365679B8 (en) 2021-03-10
WO2017068097A1 (en) 2017-04-27
EP3365679A1 (en) 2018-08-29
KR102561377B1 (ko) 2023-07-28
JP2018533009A (ja) 2018-11-08
KR20180069904A (ko) 2018-06-25
EP3365679B1 (en) 2020-12-30
CN108369234B (zh) 2020-12-01

Similar Documents

Publication Publication Date Title
BR112018008014A2 (pt) método de identificação de indivíduos portadores de carcinoma e uso de cyfra 21-1 e cea
NZ741324A (en) Anti-cd47 antibodies and methods of use
EA202091540A1 (ru) Антитела к lilrb2
JP2015536519A5 (pt)
BR112017009728A2 (pt) anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o anticorpo, composição, usos de um anticorpo e métodos de tratamento de um distúrbio
EA201691605A1 (ru) Стеклянный лист с кодом идентификации
BR112019000621A2 (pt) anticorpos tgfss, métodos e usos
BR112016002101A2 (pt) propante, e, métodos de fabricação e formação de um propante
BR112017008186A2 (pt) fluidos de estimulação de líquido e gás natural de qualidade y, sistemas e método
GB2543884A (en) Ampholyte polymers and methods of treating subterranean formations with the same
BR112019006865A2 (pt) caspases induzíveis e métodos para uso
MX2020010947A (es) Metodos de tratamiento de enfermedad de alzheimer.
BR112017016897A2 (pt) cepas fúngicas e métodos de uso
TW201614237A (en) Markers for identifying patients responsive to anti-PD-L1 antibody therapy
EA201790549A1 (ru) Предиктивные и прогностические биомаркеры, связанные с антиангиогенной терапией злокачественной опухоли
EP3683321A3 (en) Methods relating to circulating tumor cell clusters and the treatment of cancer
BR112016023607A2 (pt) uso médico de compostos de artemisinina e agonistas de gefirina
TR201909951T4 (tr) Kanser olduğundan şüphelenilen bir hastanın aflibersept ile tedavisinin sonucunun öngörülmesine yönelik yöntem.
UY35718A (es) Anticuerpos anti-csf-1r: métodos de expresión de los mismos.
CL2019002323A1 (es) Anticuerpo dirigido a il-13ra2 y su uso.
CO2017010808A2 (es) Sistemas y métodos para la vigilancia activa del cancer de próstata
PH12021500009A1 (en) Rna molecules comprising non-canonical base pairs
CL2015002705A1 (es) Anticuerpos anti-cd52.
BR112016021739A2 (pt) Método para preparar um poloxâmero para uso em um meio de cultura de célula
MX363679B (es) Metodo para diagnosticar cancer.

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]